Lansoprazole Capsule, Delayed Release
Product Images NDC 68071-2274

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 68071-2274). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2274 6)

This is a description of Lansoprazole15mg capsules manufactured by NuCare Pharmaceuticals, Inc. The capsules are delayed-release and contain 15mg of Lansoprazoke USP in the form of enteric-coated pellets. Each bottle contains 60 capsules, with the NDC code 68071-2274-06. The capsules are green and white, oblong-shaped, and have "Lifestar" imprinted on the cap and "806" on the body. They should be stored at a controlled temperature of 59-86°F and kept out of reach of children. The expiration date and lot number are also printed on the packaging. For any concerns, contact 1-800-FDA-1088.*

FDA Label Image

F53ca2be-a290-4157-ad95-d24dfe3344f9-01 (F53ca2be A290 4157 Ad95 D24dfe3344f9 01)

FDA Label Image

F53ca2be-a290-4157-ad95-d24dfe3344f9-02 (F53ca2be A290 4157 Ad95 D24dfe3344f9 02)

This is a chart showing the mean severity of heartburn experienced by patients receiving different treatments over a period of 6 days. The treatments include a placebo, lansoprazole 15mg, and lansoprazole 30mg. The mean severity of heartburn is rated on a scale of 0 to 3, with 0 indicating no heartburn and 3 indicating severe heartburn.*

FDA Label Image

F53ca2be-a290-4157-ad95-d24dfe3344f9-03 (F53ca2be A290 4157 Ad95 D24dfe3344f9 03)

The text is describing a chart that shows the mean severity of night heartburn for evaluable patients in a study over a course of days from the start of treatment. The severity is rated on a scale of 0 to 3, with 0 being no heartburn and 3 being severe heartburn. The chart compares the severity of heartburn for patients taking a placebo, lansoprazole 15mg QD, and lansoprazole 30mg QD. The chart shows that on average, patients taking lansoprazole experienced less severe heartburn than those taking the placebo, and those taking the higher dose of lansoprazole experienced even less severe heartburn than those taking the lower dose.*

FDA Label Image

F53ca2be-a290-4157-ad95-d24dfe3344f9-06 (F53ca2be A290 4157 Ad95 D24dfe3344f9 1)

FDA Label Image

F53ca2be-a290-4157-ad95-d24dfe3344f9-07 (F53ca2be A290 4157 Ad95 D24dfe3344f9 2)

FDA Label Image

Image (F53ca2be A290 4157 Ad95 D24dfe3344f9 6)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.